Curis, Inc. (NASDAQ:CRIS) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET

Company Participants

Diantha Duvall - Chief Financial Officer

James Dentzer - President and Chief Executive Officer

Robert Martell - Chief Scientific Officer

Conference Call Participants

Li Watsek - Cantor Fitzgerald

Yale Jen - Laidlaw & Company

Laura Hillman - Raymond James

Operator

Good morning, and welcome to the Curis First Quarter 2023 Business Update Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Diantha Duvall, Curis' Chief Financial Officer. Ms. Diantha, please go ahead.

Diantha Duvall

Thank you, and welcome to the Curis first quarter 2023 Business Update Call. Before we begin, I would like to encourage everyone to go to the Investors section of our website @www.curis.com to find our fourth quarter 2023 business update release and related financial tables.

I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Dentzer, President and Chief Executive Officer; and Bob Martell, Chief Scientific Officer, and Jonathan Zung, our newly appointed Chief Development officer. We will also be available for a question-and-answer period at the end of the call.

I'd like now to turn the call over to Jim.

James Dentzer

Thank you, Diantha. Good afternoon, everyone, and welcome to Curis' First Quarter Business Update Call. . This past quarter, we made important progress with our lead clinical candidate, emavusertib. As we mentioned in our March update, we completed enrolling the additional patients requested by FDA ahead of schedule, which we believe is indicative of both the clear unmet need in leukemia and the excitement among the clinical community for this novel agent.

We are collecting and analyzing data from these patients this quarter and expect to discuss these data with the FDA in the third quarter. We are optimistic that these data will be sufficient for the FDA to allow us to proceed with a Recommended Phase 2 Dose and move into the expansion phase of our take aim leukemia study.

We're also enrolling patients with Primary Central Nervous System Lymphoma or PCNSL, and treating them with Emavusertib in combination with the BTK inhibitor ibrutinib in our TakeAim Leukemia study. We believe emavusertib in combination with ibrutinib has the potential to be an important new therapy in PCNSL, which is an orphan population of patients with high unmet need.